PHYTO PURE LIQ 35.8 MG / 15 ML
DWARF PINE : 35.8 MG / 15 ML CASCARA SAGRADA : 15 MG / 15 ML TARAXACUM OFFICINALE WEBER : 34.8 MG / 15 ML · DIN 00863246 · NOBEL PHARM ENR.
Health Canada status: CANCELLED POST MARKET
What is PHYTO PURE LIQ?
PHYTO PURE LIQ 35.8 MG / 15 ML contains DWARF PINE : 35.8 MG / 15 ML CASCARA SAGRADA : 15 MG / 15 ML TARAXACUM OFFICINALE WEBER : 34.8 MG / 15 ML. It is listed in the Health Canada Drug Product Database under DIN 00863246, held by NOBEL PHARM ENR., supplied as LIQUID for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00863246 |
|---|---|
| Brand name | PHYTO PURE LIQ |
| Generic / active ingredient | DWARF PINE : 35.8 MG / 15 ML CASCARA SAGRADA : 15 MG / 15 ML TARAXACUM OFFICINALE WEBER : 34.8 MG / 15 ML |
| Manufacturer | NOBEL PHARM ENR. |
| Strength | 35.8 MG / 15 ML |
| Dosage form | LIQUID |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A06AB57 CASCARA, COMBINATIONS |
| AHFS class | 56:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-1997 |
| Original market date | 1990-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A06AB57 CASCARA, COMBINATIONS. 0 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACIDOBYL & CASCARA | 20 MG | TABLET | DESBERGERS LTÉE, DIVISION OF TECHNILAB INC. | CANCELLED POST MARKET | DIN 00086762 |
| ALSILAX | 528 MG / 30 ML | LIQUID | ALSI CIE LTEE | CANCELLED POST MARKET | DIN 00468355 |
| BYLIUM LIQ | 176 MG / 10 ML | LIQUID | SUPERCO ENR. | CANCELLED POST MARKET | DIN 00378607 |
| CHOLETOL | 17.6 MG | LIQUID | LES LABORATOIRES VACHON INC. | CANCELLED POST MARKET | DIN 00482382 |
| DEPURATEX | 100.9 MG / 100 ML | LIQUID | LABORATOIRE LALCO INC. | CANCELLED POST MARKET | DIN 00491594 |
| DEPURATON | 100.9 MG / 100 ML | LIQUID | BIODO ENRG | CANCELLED POST MARKET | DIN 00491632 |
| ELIXIR 101 | 14.4 MG | LIQUID | FREGA INC. | CANCELLED POST MARKET | DIN 00477168 |
| FORMULA 100 | 15 MG / 28 ML | LIQUID | VITALAB | CANCELLED POST MARKET | DIN 00840866 |
| HERBASAN | 209 MG / 30 ML | LIQUID | SANTÉ NATURELLE (AG) LTÉE | CANCELLED POST MARKET | DIN 00559849 |
| HERBATOL LAX LIQ | 15 MG / 15 ML | LIQUID | CARDINAUX ENRG LES PRODUITS NATURELS | CANCELLED POST MARKET | DIN 00731889 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.